CCL2 and ovarian neoplasm: In addition to NY-ESO-1-specific autoantibodies, several factors expressed by ovarian tumors have shown a positive correlation with tumor-infiltrating T cells, including the chemokines CXCL9, CCL21, CCL22 [8], CCL2 and CCL5 [35]; p53 mutations [36]; and MHC class I [37].